CARAC
LOE Approachingfluorouracil cream, 0.5%
NDATOPICALCREAM
Approved
Oct 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
5/8 — Partial
CARAC (fluorouracil cream, 0.5%) is nucleic acid synthesis inhibitors [moa]. First approved in 2000.
Drug data last refreshed 9h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CARAC is a topical fluorouracil cream (0.5%) approved in 2000 for dermatological use, containing a nucleoside metabolic inhibitor that blocks nucleic acid synthesis. The drug is applied directly to skin lesions and works by inhibiting DNA synthesis in rapidly dividing cells. It is indicated for treatment of actinic keratosis and other precancerous skin conditions.
$0.049BPart D
LOE ApproachingDeclining
Product is in late maturity with modest Part D utilization and faces significant competitive pressure, suggesting a lean commercial team focused on retention rather than growth.
Mechanism of Action
Nucleic Acid Synthesis Inhibitors
Pharmacologic Class:
Nucleoside Metabolic Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Carac & PDT Combination in the Treatment Of Actinic Keratoses
Started Aug 2008
60 enrolled
Actinic Keratoses
Career Relevance
Working on CARAC offers limited career growth given the product's late-lifecycle stage and declining market dynamics; roles are primarily defensive and focused on maintaining market share rather than expansion. This position is best suited for professionals seeking a stable but non-growth-oriented assignment or those building expertise in mature dermatology portfolios.
Brand Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.